GOLDEN AGE HEALTH CORPORATE POST
From innovation to access - building a new healthcare bridge between China and the world
Golden Age Health recently completed an important visit to Jinan, the capital of Shandong Province, focused on developing deeper collaboration across government, healthcare, biopharma and investment groups.
The Golden Age Health delegation - Michel Vounatsos, Executive Chairman & Co-Founder, Yossi Ben-Amram, Co-Founder, CSO & COO, and Brook Wu, CEO of Golden Age Health China - engaged with senior leaders across Jinan’s healthcare and innovation ecosystem.
Shandong is one of China’s most important economic provinces, with approximately 100 million inhabitants and GDP exceeding RMB 10 trillion. Jinan has developed a substantial biopharmaceutical and healthcare cluster encompassing R&D, manufacturing, healthcare delivery, commercialization and investment.
A central part of the visit was our meeting with Dr. Yu Haitian, Mayor of Jinan, together with senior representatives of the Jinan Municipal Government and Jinan Innovation Zone.
The discussions focused on a shared objective - connecting global healthcare innovation with the capabilities, infrastructure, capital and patient needs of China, while creating pathways for Chinese innovation to reach international markets.
Our delegation also held substantive discussions with Jinan Hi-Tech Holding Group and the local investment ecosystem. We particularly appreciate David Xu, Managing Partner of MCGF, for his engagement and continued support in developing the relationship between Golden Age Health and Shandong.
The program included an important visit to Qilu Pharmaceutical, one of China’s leading pharmaceutical companies, where discussions explored potential areas of collaboration involving selected products, capabilities and markets.
For Golden Age Health, this represents an important extension of our model - not simply bringing global innovation into China, but increasingly creating a two-way commercialization bridge between China and international markets.
We were also delighted to be joined by Dr. Wang, CEO of Innostellar Biologics, an existing Golden Age Health partner.
Golden Age Health and Innostellar are working together to facilitate access to LX101, a gene therapy targeting RPE65-associated inherited retinal disease, for eligible patients through the Hainan pilot-zone pathway - demonstrating how innovative partnerships can translate science into real-world patient access.
The Jinan visit brought together the essential components of the ecosystem Golden Age Health is building:
We sincerely thank Mayor Yu Haitian and the Jinan leadership, Jinan Innovation Zone, Jinan Hi-Tech Holding Group, Qilu Pharmaceutical, David Xu and MCGF, Dr. Wang and Innostellar, and all our hosts for the warm welcome and highly substantive discussions.
#GoldenAgeHealth #China #Shandong #Jinan #PatientAccess #RareDisease #Biopharma #HealthcareInnovation #GlobalHealth
